This review is focused on the ovarian cancer risk reduction management in BRCA mutation carriers and is intended to assist with clinical decision-making. Obviously, treatment decisions must be based on the available evidence. Despite risk-reducing salpingo-oophorectomy is firmly recommended, several separate questions can be raised to address the variety of intense controversy of this approach. A special emphasis lies in the effective preventive surgical measure against ovarian cancer risk, in an attempt to detect the optimal timing and mitigate the impact on patients. The long term implications of risk-reducing salpingo-oophorectomy as well as hormone replacement therapy are also actively debated. This is expected to represent an opportunity for improved management modelling of BRCA mutated patients.

这篇综述的重点是BRCA突变携带者的卵巢癌风险降低管理，旨在协助临床决策。显然，治疗决策必须基于现有证据。尽管强烈建议降低输卵管输卵管卵巢切除术的风险，但仍可以提出几个单独的问题来解决这种方法引起的激烈争议。特别强调的是针对卵巢癌风险的有效预防性手术措施，旨在发现最佳时机并减轻对患者的影响。降低风险的输卵管卵巢切除术以及激素替代疗法的长期意义也受到了积极的争论。预计这将为改进BRCA突变患者的治疗模型提供机会。